InvestorsHub Logo
Followers 132
Posts 6427
Boards Moderated 0
Alias Born 05/13/2014

Re: Charliebee post# 22202

Wednesday, 09/23/2020 7:11:28 AM

Wednesday, September 23, 2020 7:11:28 AM

Post# of 44690
Totally crazy stuff ... glad I wasn’t late for the party ... I see they’re getting more and more media exposure & I agree hands-down - no issues on the EUA... Amazing results and limited side effects:

“ Patients treated with RLF-100™ demonstrated a 3-fold advantage in survival, recovery from respiratory failure, and other parameters indicative of meaningful clinical improvement. Hypotension was seen in two aviptadil patients and was successfully managed with pressors. Diarrhea was seen in 4/21 aviptadil-treated patients and 3/30 control patients. The results have been submitted to a peer-reviewed journal.

The EUA application covers the same type of patients whom FDA has already allowed to receive treatment under the Expanded Access protocol authorized by the Agency in July. Tragically, we have found that many patients who might benefit from the Expanded Access protocol are hospitalized in centers that do not allow patients access to investigational drugs," said Jonathan Javitt, MD, MPH, Chairman and CEO of NeuroRx, "Our staff is working around the clock to address requests for RLF-100™ under the appropriate mechanism. All too often, patients of color and those of lower socioeconomic status are denied access."